TABLE 1.
Clinical characteristics of responder and nonresponder groups
| Characteristic | Groupa
|
||
|---|---|---|---|
| R | NR | P valuec | |
| VL at baseline (105) (median) | 4.5 (0.27∼31.0)* | 2.0 (0.06∼9.3) | NS |
| VL at 6 mo (105) (median) | 1.6 (0.02∼8.2)* | 3.0 (0.05∼29.0) | NS |
| CD4 at baseline (absolute) (median) | 220 (100∼400) | 310 (100∼500) | NS |
| CD4 at baseline (%) | 12.5 (24.3∼4.4) | 17.8 (24.0∼3) | NS |
| Gender (male/female) | 7/10 | 4/6 | NS |
| Age (yr) (median) | 35 (23∼60) | 27 (23∼37) | <0.03 |
| CXR at t0 (grade 3) (%) | 83 | 90 | NS |
| CXR improvement (grade) (%) | 75 | 33 | 0.05 |
| Hgbb at baseline (median) | 9.9 (8.7∼13.6)** | 10.5 (8.5∼12.7) | NS |
| Hgb at 2 mo (median) | 12.1 (10.1∼13.5)** | 11.3 (9.9∼13.5) | NS |
| Karnofsky score at baseline (median) | 80 (70∼90) | 80 (80∼90) | NS |
a
R, responder group; NR, nonresponder group. P < 0.001; P < 0.05.
b
Hgb, hemoglobin.
c
NS, not significant.